NasdaqGS - Delayed Quote USD

AVROBIO, Inc. (AVRO)

1.3500

+0.1200

(+9.76%)

At close: May 13 at 4:00 PM EDT

1.3300

-0.02

(-1.48%)

After hours: May 13 at 7:41 PM EDT

Key Events

Loading Chart for AVRO

9/21 12:03 PM

DELL

Previous Close 1.2300
Open 1.2300
Bid 1.3300 x 400
Ask 1.3600 x 500
Day's Range 1.2200 - 1.3650
52 Week Range 0.5700 - 1.7000
Volume 861,647
Avg. Volume 211,927
Market Cap (intraday) 60.607M
Beta (5Y Monthly) 1.24
PE Ratio (TTM) 5.00
EPS (TTM) 0.2700
Earnings Date Aug 8, 2024 - Aug 12, 2024
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 2.00

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

www.avrobio.com

13

Full Time Employees

December 31

Fiscal Year Ends

Sector

Industry

Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

AVRO

0.74%

S&P 500

9.47%

1-Year Return

AVRO

110.94%

S&P 500

26.61%

3-Year Return

AVRO

84.64%

S&P 500

28.51%

5-Year Return

AVRO

93.09%

S&P 500

81.21%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

1.3500

+9.76%

Mkt Cap 60.607M

Industry Biotechnology

Assembly Biosciences, Inc.

13.39

-0.07%

Mkt Cap 73.823M

Industry Biotechnology

Bolt Biotherapeutics, Inc.

1.3300

+5.56%

Mkt Cap 50.71M

Industry Biotechnology

Kezar Life Sciences, Inc.

0.7475

-3.26%

Mkt Cap 54.419M

Industry Biotechnology

27.75

+2.29%

Mkt Cap 331.044M

Industry Biotechnology

MeiraGTx Holdings plc

5.14

+1.38%

Mkt Cap 330.536M

Industry Biotechnology

Autolus Therapeutics plc

4.0100

+0.50%

Mkt Cap 1.066B

Industry Biotechnology

1.6000

-3.03%

Mkt Cap 44.757M

Industry Biotechnology

6.82

-3.45%

Mkt Cap 19.198M

Industry Biotechnology

Replimune Group, Inc.

6.59

+2.81%

Mkt Cap 404.546M

Industry Biotechnology

2.6400

-2.58%

Mkt Cap 127.001M

Industry Biotechnology

Valuation Measures

As of 5/13/2024

Market Cap

60.61M
Enterprise Value

-29.65M
Trailing P/E

1.96
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

--
Price/Book (mrq)

0.68
Enterprise Value/Revenue

--
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-40.62%
Return on Equity (ttm)

14.29%
Revenue (ttm)

--
Net Income Avi to Common (ttm)

12.16M
Diluted EPS (ttm)

0.2700

Balance Sheet and Cash Flow

Total Cash (mrq)

98.02M
Total Debt/Equity (mrq)

0.93%
Levered Free Cash Flow (ttm)

-36.24M

AVRO does not have Company Insights

AUTL Autolus Therapeutics plc

4.0100

+0.50%

MGTX MeiraGTx Holdings plc

5.14

+1.38%

ASMB Assembly Biosciences, Inc.

13.39

-0.07%

KZR Kezar Life Sciences, Inc.

0.7475

-3.26%

EVLO Evelo Biosciences, Inc.

0.0400

-20.00%

BCEL Atreca, Inc.

0.0943

+4.61%

ADVM Adverum Biotechnologies, Inc.

9.17

-1.40%

CTMX CytomX Therapeutics, Inc.

1.8900

-4.55%

REPL Replimune Group, Inc.

6.59

+2.81%

CRNX Crinetics Pharmaceuticals, Inc.

47.93

-0.15%

YMAB Y-mAbs Therapeutics, Inc.

12.19

-0.73%

SRRK Scholar Rock Holding Corporation

13.64

+2.17%

NXTC NextCure, Inc.

1.6000

-3.03%

SLDB Solid Biosciences Inc.

9.75

-6.16%

PASG Passage Bio, Inc.

1.4800

+0.68%

MRSN Mersana Therapeutics, Inc.

2.6200

-3.32%